StreetInsider.com News Articles

Selloff in this medical stock looks "overdone": TD Cowen

Mon, 19 Oct 2026 12:00:00 -0400

Sustained selling pressure in a breast implant maker after its second-quarter earnings release has become disconnected from the company's underlying operating performance, TD Cowen analysts argue, reiterating a Buy rating.

The team led by Joshua Jennings said Establishment Labs (NASDAQ: ESTA) appears to be "on the cusp of an FDA decision that could unlock the U.S. breast reconstruction market" for its flagship Motiva implant line, a key catalyst behind its view that the recent selloff is overdone.

Analysts said investors have focused on a deceleration in revenue growth outside the U.S., which could turn negative in the second half of 2026. They

Selloff in this medical stock looks "overdone": TD Cowen

Mon, 19 Oct 2026 12:00:00 -0400

Analysts said investors have focused on a deceleration in revenue growth outside the U.S., which could turn negative in the second half of 2026. They

Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29

Mon, 19 Oct 2026 08:00:00 -0400

NEW YORK--(BUSINESS WIRE)--

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2026, before the market opens on Thursday, October 29, 2026, and will host a conference call at 8:30 AM ET that day to discuss those results.

To participate in the conference call, Dial: (+1) 877-407-8037 (US & Canada) / (+1) 201-689-8037 (International). The call will also be available via live or archived webcast on the “Investor

Establishment Labs® to Announce Third Quarter 2026 Financial Results on October 29

Mon, 19 Oct 2026 08:00:00 -0400

NEW YORK--(BUSINESS WIRE)--

To participate in the conference call, Dial: (+1) 877-407-8037 (US & Canada) / (+1) 201-689-8037 (International). The call will also be available via live or archived webcast on the “Investor

TD Cowen on Establishment Labs Inc. (ESTA): 'The Selloff Looks Overdone as a Major FDA Catalyst Approaches'

Thu, 15 Oct 2026 09:25:30 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $117.00 price target on Establishment Labs Inc. (NASDAQ: ESTA).

The analyst commented: "The Selloff Looks Overdone as a Major FDA Catalyst Approaches; We believe the sustained selling pressure in Establishment Labs following its 2Q26 earnings release has become increasingly disconnected from the company's underlying operating performance and the magnitude of its approaching market expansion opportunities. Most importantly, ESTA appears to be on the cusp of an FDA decision that could unlock the U.S. breast reconstruction market. Reiterate Buy."

For an analyst ratings summary and ratings history on Establishment Labs Inc. click

Form 8-K ESTABLISHMENT LABS HOLDI For: Oct 14

Thu, 15 Oct 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20261015/27189080.html

Stifel Starts Establishment Labs Inc. (ESTA) at Buy

Wed, 14 Oct 2026 16:13:19 -0400

Stifel analyst Joseph Federico initiates coverage on Establishment Labs Inc. (NASDAQ: ESTA) with a Buy rating and a price target of $85.00.

The analyst comments "We are initiating coverage of Establishment Labs with a Buy rating, supported by +DD % top-line growth (in Med-Tech), strong expected share gains, and an underlying market that may be healthier than feared. Despite select concerns, our diligence among 66 U.S. plastic surgeons suggests that the breast augmentation market can maintain growth (albeit modest) for years to come, and our respondents’ market share expectations (pages 24-30) indicate that Establishment Labs is poised to capture meaningful share

Stifel Starts Establishment Labs Inc. (ESTA) at Buy

Wed, 14 Oct 2026 16:13:19 -0400

Stifel analyst Joseph Federico initiates coverage on Establishment Labs Inc. (NASDAQ: ESTA) with a Buy rating and a price target of $85.00.

FDA approves 28 new sizes of Motiva breast implants from Establishment Labs

Mon, 05 Oct 2026 08:01:26 -0400

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that the U.S. Food and Drug Administration has approved an expanded range of Motiva SmoothSilk Round and Motiva SmoothSilk Ergonomix breast implants for sale in the United States.

The approval adds 28 new sizes to the company's U.S. portfolio, including implants as small as 105 cc. The expanded range covers Mini, Demi, and Full profiles across both product lines, with new combinations of base, projection, and volume. The company said the new sizes will be commercially available before the end of the year.

The 19 new Motiva SmoothSilk Round sizes span Mini Profile (105 cc

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®

Mon, 05 Oct 2026 08:00:00 -0400

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States.

The approval adds 28 new sizes to the Motiva U.S. portfolio, including implants as small as 105 cc, and expands the combinations of base, projection and volume available across Mini, Demi and Full profiles in both the Motiva SmoothSilk Round and

Establishment Labs® Receives FDA Approval for Additional Sizes of Motiva Implants®

Mon, 05 Oct 2026 08:00:00 -0400

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States.

Form 4 ESTABLISHMENT LABS HOLDI For: Sep 30 Filed by: Gillin Leslie

Fri, 02 Oct 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20261002/27143512.html

Form 4 ESTABLISHMENT LABS HOLDI For: Sep 30 Filed by: SCHUTTER EDWARD J

Fri, 02 Oct 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20261002/27143483.html

Form 4 ESTABLISHMENT LABS HOLDI For: Sep 30 Filed by: LEWIN NICHOLAS SHERIDAN

Fri, 02 Oct 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20261002/27143478.html

Form 4 ESTABLISHMENT LABS HOLDI For: Sep 30 Filed by: Slotkin Bryan

Fri, 02 Oct 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20261002/27143468.html

Form 4 ESTABLISHMENT LABS HOLDI For: Sep 30 Filed by: Custin Ann

Fri, 02 Oct 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20261002/27143438.html

Establishment Labs presents breast tissue data, expands product line

Mon, 21 Sep 2026 08:04:11 -0400

Establishment Labs Holdings Inc. (NASDAQ: ESTA) presented new clinical and scientific data on breast tissue preservation and its minimally invasive platform at the 11th World Symposium on Ergonomic Implants (WSEI) in Istanbul, Turkey.

The company also announced product line extensions for its Mia and Preservé devices, adding new sizes and supporting tools. The symposium drew more than 1,000 plastic surgeons from 57 countries and featured 127 scientific presentations and educational sessions.

Among the data presented were findings from a four-part, peer-reviewed supplement published in the Aesthetic Surgery Journal, authored by more than 25 contributors including plastic and reconstructive surgeons, anatomists, pathologists, and

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

Mon, 21 Sep 2026 08:00:00 -0400

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcements took place during the 11th World Symposium on Ergonomic Implants (WSEI), in Istanbul, Turkey.

WSEI brought together over 1,000 plastic surgeons from 57 countries and featured 127 individual scientific presentations and educational

Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants

Mon, 21 Sep 2026 08:00:00 -0400

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of new clinical and scientific data supporting Breast Tissue Preservation and its Minimally Invasive Platform. Establishment Labs also announced the product line extensions of both Mia® and Preservé™ with new sizes and supporting tools. The announcements took place during the 11th World Symposium on Ergonomic Implants (WSEI), in Istanbul, Turkey.
WSEI brought together over 1,000 plastic surgeons from 57 countries and featured 127 individual scientific presentations and educational

Form 4 ESTABLISHMENT LABS HOLDI For: Aug 20 Filed by: Caldini Filippo

Wed, 26 Aug 2026 17:07:00 -0400
si-local-file:///var/storage/secattach/20260826/26982743.html

Form 4 ESTABLISHMENT LABS HOLDI For: Aug 20 Filed by: Caldini Filippo

Wed, 26 Aug 2026 17:07:00 -0400
si-local-file:///var/storage/secattach/20260826/26982743.html

Citi upgrades Establishment Labs to Buy with $92 target

Thu, 13 Aug 2026 06:34:36 -0400
(Updated - August 13, 2026 6:34 AM EDT)
Citi analyst Joanne Wuensch upgraded Establishment Labs Inc. (NASDAQ: ESTA) from Neutral to Buy, maintaining a price target of $92.00, according to a research note.
The upgrade follows a quarter in which ESTA shares fell 13.4% despite reporting total revenue of $67.5M, up 31.7% year-over-year excluding foreign exchange, which exceeded FactSet consensus of $65.8M. U.S. sales reached $24.7M, up approximately 140% year-over-year, while international sales came in at $42.8M, up 4.4%.
The company reported an EPS loss of $0.39, wider than the consensus estimate of a $0.34 loss. Establishment Labs raised its 2026 revenue guidance

Citi upgrades Establishment Labs to Buy with $92 target

Thu, 13 Aug 2026 06:34:36 -0400
(Updated - August 13, 2026 6:34 AM EDT)
Citi analyst Joanne Wuensch upgraded Establishment Labs Inc. (NASDAQ: ESTA) from Neutral to Buy, maintaining a price target of $92.00, according to a research note.
The upgrade follows a quarter in which ESTA shares fell 13.4% despite reporting total revenue of $67.5M, up 31.7% year-over-year excluding foreign exchange, which exceeded FactSet consensus of $65.8M. U.S. sales reached $24.7M, up approximately 140% year-over-year, while international sales came in at $42.8M, up 4.4%.
The company reported an EPS loss of $0.39, wider than the consensus estimate of a $0.34 loss. Establishment Labs raised its 2026 revenue guidance

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

Wed, 12 Aug 2026 09:15:00 -0400

News Provided by USA News Group on behalf of Conexeu Sciences Inc.
RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order opportunity that the drugs themselves were never designed to address. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

Wed, 12 Aug 2026 09:15:00 -0400

News Provided by USA News Group on behalf of Conexeu Sciences Inc.
RENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order opportunity that the drugs themselves were never designed to address. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to